2019-05-10T10:22:52-05:00 2018-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2018-01-01 206745475 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION ADEN 7812489699 PO BOX 442 NEEDHAM MA 02494 JEFFREY A KAUFMAN EXECUTIVE DIRECTOR 7812489699 2019-05-10 1 DEBORAH A HOPKINS P00167843 4012742001 70.164.241.209 2019-05-10 07:13:26 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 6C9B1A35775087DBDB8A6D25ECA509C7F6C27838 2018 2019-02-21 02:37:17Z JEFFREY A KAUFMAN PO BOX 442 NEEDHAM MA 02494 2043147 0 X WWW.ACCRF.ORG X 2005 MA SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA. 6 6 1 2 0 0 1329755 1809421 107991 147986 7996 21048 156941 64692 1602683 2043147 559951 744865 0 0 81208 122586 0 0 1226 523569 427003 1164728 1294454 437955 748693 1623360 1935482 867661 431090 755699 1504392 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE. 0 0 113394 100000 SPECIMENS AND MODELS: ACCRF SUPPORTS AND COORDINATES THE DEVELOPMENT AND DISTRIBUTION OF BIOBANKING, CELL LINE AND ANIMAL MODEL RESOURCES FOR RESEARCHERS. THESE RESOURCES ARE THE BUILDING BLOCKS UPON WHICH ALL BASIC, TRANSLATIONAL AND CLINICAL RESEARCH ARE CONSTRUCTED. 538751 475115 BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY THE MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEELS OF THE DISEASE. 577867 169750 147986 TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL BENEFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS. 1230012 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 2 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 1 1 0 0 MA NY CA CT FL MI NC NH NY OH PA VA X MARNIE A KAUFMAN 7814491757 60 SAVOY ROAD NEEDHAM MA 02492 X JEFFREY A KAUFMAN EXECUTIVE DIRECTOR/BOARD CHAIR 50.00 X X 0 0 0 THOMAS DILENGE BOARD VICE CHAIR 5.00 X X 0 0 0 RALPH MOLLIS TREASURER 5.00 X X 0 0 0 LISA BAKRI DIRECTOR 5.00 X 0 0 0 KARA GELB DIRECTOR (UP TO 7/18) 5.00 X 0 0 0 MARNIE A KAUFMAN DIRECTOR 25.00 X 0 0 0 DOUGLAS MEYER DIRECTOR 5.00 X 0 0 0 NICOLE SPARDY BURR SCIENTIFIC PROGRAM OFFICER 40.00 X 107500 0 0 107500 0 0 1 0 0 0 0 1809421 50809 1809421 RESEARCH STUDIES 621500 147986 147986 147986 21048 21048 PY GRANTS RETURNED 900099 64692 64692 64692 2043147 147986 0 85740 617115 617115 127750 127750 114362 108644 4574 1144 8224 7813 329 82 19521 19521 23134 23134 33018 19258 13760 9571 9571 1898 1898 RESEARCH STUDIES EXPENS 193098 193098 DRUG SCREENING EXPENSE 146763 146763 1294454 1230012 63216 1226 289860 204558 1308897 1659355 15093 62567 9510 9002 1623360 1935482 400236 35461 455750 395629 11675 0 867661 431090 X 755699 1504392 755699 1504392 1623360 1935482 748693 0 X 0 1 X 1 0 X 483168 1667904 1087972 1329755 1809421 6378220 483168 1667904 1087972 1329755 1809421 6378220 453391 5924829 6303 3424 10503 7996 21048 49274 156941 64692 221633 6649127 309333 0.89110 0.83790 X 0 X 2104143 125688 125688 1978455 64692 64692 2043147 1355450 125688 -64692 60996 1294454 0 1294454 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH THEIR TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE FOUNDATION ANNUALLY FILES IRS FORM 990 - RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. PART XI, LINE 4B - OTHER ADJUSTMENTS: PRIOR YEAR GRANTS RETURNED 64,692. PART XII, LINE 2D - OTHER ADJUSTMENTS: PRIOR YEAR GRANTS RETURNED -64,692. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUPPORT FOR RESEARCH RELATING TO ADENOID CYSTIC CARCINOMA 32750 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUPPORT FOR RESEARCH RELATING TO ADENOID CYSTIC CARCINOMA 95000 0 0 0 0 0 0 127750 0 127750 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SUPPORT FOR DEVELOPMENT OF MYB DNA VACCINE 95000 CHECK OR FUND TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT FOR STUDY OF FUSIONS IN CTDNA 24750 CHECK OR FUND TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SUPPORT FOR STUDY OF RNASEQ SUBGROUPS 8000 CHECK OR FUND TRANSFER 0 3 0 0 0 0 0 0 0 PART I, LINE 2: ALL FOREIGN GRANTS ARE MADE TO MAJOR RESEARCH INSTITUTIONS OR HOSPITALS WITH INTERNATIONAL REPUTATIONS. IN ADDITION TO INTERIM WRITTEN REPORTS ON RESEARCH PROJECTS AND A FINAL REPORT FOLLOWING PROJECT COMPLETION, ACCRF ANNUALLY MEETS WITH EACH OF THE FOREIGN GRANTEES TO RECEIVE AN ORAL REPORT ON THE RESEARCH PROJECTS. 1 M D ANDERSON CANCER CENTER P O BOX 4486 HOUSTON TX 772104486 746001118 501(C)(3) 100000 SUPPORT FOR TRANSGENIC MOUSE MODEL FOR SALIVARY ACC AND CELL LINE BANKING MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 129486 SUPPORT FOR ADVANCING MYB SMALL MOLECULE BINDERS COLUMBIA UNIVERSITY 116TH STREET AND BROADWAY NEW YORK NY 10027 135598093 501(C)(3) 200000 SUPPORT FOR THE STUDY OF USING "SINGLE-CELL GENOMICS" TO DE-CONVOLUTE THE CELL COMPOSITION OF ACCS AND GUIDE THE DESIGN OF NOVEL ANTI-TUMOR DRUG COMBINATIONS. DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 25000 SUPPORT FOR STUDY OF PEMBRO/RT CORRELATIVES UNIVERSITY OF MICHIGAN 500 S STATE STREET ANN ARBOR MI 48109 386006309 501(C)(3) 25000 SUPPORT FOR THE STUDY OF ENTINOSTAT AND CISPLATIN UNIVERSITY OF NEW MEXICO 1155 UNIVERSITY BLVD SE ALBUQUERQUE NM 871064320 856000642 501(C)(3) 137629 SUPPORT FOR THE STUDY OF RNASEQ SUBGROUPS 6 0 PART I, LINE 2: ACCRF TYPICALLY REQUIRES INTERIM REPORTING ON RESEARCH PROJECTS EVERY SIX MONTHS AS WELL AS A FINAL REPORT FOLLOWING PROJECT COMPLETION. X 1 50809 EXCHANGE RATE FMV 0 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 THE EXECUTIVE DIRECTOR, JEFFREY A. KAUFMAN, IS MARRIED TO A DIRECTOR ON THE BOARD, MARNIE A. KAUFMAN. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY MANAGEMENT. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL DIRECTORS. THE DIRECTORS ARE ASKED IF THEY HAVE ANY QUESTIONS OR COMMENTS AND A GENERAL REVIEW OF THE FORM IS CONDUCTED BY MANAGEMENT. REVISIONS AND CORRECTIONS ARE MADE AS NECESSARY. SUBSEQUENTLY, THE FORM IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C A FORMAL PROCESS IS UNDERTAKEN EACH YEAR TO MONITOR AND ENFORCE THE CONFLICT OF INTEREST POLICY CONTAINED WITHIN THE BYLAWS. EACH JANUARY, AN ANNUAL SURVEY ON CONFLICTS OF INTEREST IS COMPLETED BY EVERY DIRECTOR AND OFFICER COVERING THE PRIOR CALENDAR YEAR. ALL BUSINESS RELATIONSHIPS, IF ANY, ARE REPORTED TO THE BOARD OF DIRECTORS. EXCLUDING ANY INTERESTED PARTIES, A MAJORITY OF REMAINING DIRECTORS DETERMINES WHETHER A CONFLICT OF INTEREST HAS OCCURRED AND WHETHER A MORE ADVANTAGEOUS TRANSACTION IS AVAILABLE TO THE FOUNDATION THAT WOULD NOT LEAD TO A CONFLICT OF INTEREST. THE BOARD IS CHARGED WITH TAKING APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION IN THE CASE OF A VIOLATION OF THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15A A FORMAL STRATEGIC REVIEW, OBJECTIVE SETTING AND PERFORMANCE REVIEW PROCESS IS UNDERTAKEN EACH YEAR. THE BOARD OF DIRECTORS REVIEWS THE PERFORMANCE OF THE ORGANIZATION AND EXECUTIVE DIRECTOR, BASED ON GOALS AND OBJECTIVES PREVIOUSLY AGREED UPON DURING THE PRIOR CALENDAR YEAR AND ON A PERFORMANCE REPORT SUBMITTED BY THE EXECUTIVE DIRECTOR IN ADVANCE. THE INDEPENDENT DIRECTORS OF THE BOARD MEET SEPARATELY TO ASSESS THE EXECUTIVE DIRECTOR'S PERFORMANCE, AGREE ON A PROCESS TO INFORM THE EXECUTIVE DIRECTOR OF ANY AREAS OF NEEDED IMPROVEMENT, AND AGREE UPON A MERIT AND/OR COST OF LIVING SALARY INCREASE FOR THE DIRECTOR, SUBJECT TO AVAILABILITY OF FUNDS AND MAINTENANCE OF AN APPROPRIATE RATIO BETWEEN SUCH SALARY AND ACCRF FUNDRAISING/REVENUE TOTALS IN ANY GIVEN YEAR. THE EXECUTIVE DIRECTOR CHOSE TO NOT RECEIVE ANY COMPENSATION DURING 2017. THE BOARD OF DIRECTORS SETS PERFORMANCE OBJECTIVES AND METRICS FOR THE ORGANIZATION AND THE EXECUTIVE DIRECTOR FOR THE CURRENT CALENDAR YEAR. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS (ARTICLES OF INCORPORATION AND BY-LAWS), ITS CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. THE ORGANIZATION WILL MAIL COPIES UPON REQUEST OR PROVIDE COPIES TO THOSE WHO COME TO THE ADMINISTRATIVE OFFICES DURING NORMAL BUSINESS HOURS.